FDA Deems Genomic Breast Cancer Prognostics Class II Devices, Releases 'Special Controls' Guidance | GenomeWeb
NEW YORK (GenomeWeb News) - The US Food and Drug Administration yesterday classified gene-expression based breast cancer prognostic tests as Class II devices and released a “special controls” guidance for companies developing such tests.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.